Zhou Hangsheng, Gui Jiandong, Zhu Lijie, Mi Yuanyuan
Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu Province, 214122, People's Republic of China.
Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, 214122, People's Republic of China.
Onco Targets Ther. 2024 May 30;17:449-462. doi: 10.2147/OTT.S451108. eCollection 2024.
Methylation-mediated gene silencing is closely related to the occurrence and development of human tumors. The euchromatic histone lysine methyltransferase 2 (EHMT2, also known as G9a) is highly expressed in many tumors and is generally considered to be an oncogene, which is associated with the poor outcome of many tumors. Combined immunotherapy and immune checkpoint blockade therapy also have good efficacy and certain safety. However, there are still many difficulties in the drugs targeting G9a, and the combined effect and safety of G9a with many drugs is still under study. This article aims to summarize the role and mechanism of G9a and its inhibitors in tumors in the past two years, and to understand the application prospect of G9a from the perspective of diagnosis and treatment.
甲基化介导的基因沉默与人类肿瘤的发生发展密切相关。常染色质组蛋白赖氨酸甲基转移酶2（EHMT2，也称为G9a）在许多肿瘤中高表达，通常被认为是一种癌基因，与许多肿瘤的不良预后相关。联合免疫疗法和免疫检查点阻断疗法也具有良好的疗效和一定的安全性。然而，靶向G9a的药物仍存在许多困难，G9a与许多药物的联合效果和安全性仍在研究中。本文旨在总结过去两年中G9a及其抑制剂在肿瘤中的作用和机制，并从诊断和治疗的角度了解G9a的应用前景。
